Fig. 7
From: Targeting Pim kinases in hematological cancers: molecular and clinical review
Cellular Signaling and Genetic Alterations in Hodgkin’s and non-Hodgkin’s leukemia/lymphoma Leading to Enhanced Pim Kinase Activity. A Model depicting the regulation of Pim kinase expression and activity in various Hodgkin’s and non-Hodgkin’s lymphomas/leukemias. These include cHL (Classic Hodgkin’s Lymphoma), DLBCL (Diffuse Large B-cell Lymphoma), Follicular Lymphoma (FL), Marginal zone lymphoma (MZL), Mucosa-associated Lymphoid Tissue (MALT) lymphoma, Peripheral T-cell lymphoma (PTCL), Mantle Cell Lymphoma (MCL), Burkitt lymphoma (BL), Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL), and Adult T-cell leukemia/lymphoma (ATLL). B OncoPrint of genetic alterations from 12 cancer genomic studies on various lymphomas and leukemias. Data was collected from cBioPortal for Cancer Genomics [29, 30]. These include whole genome sequencing from 4 chronic lymphocytic leukemia (CLL) studies: CLL from Broad-2013 [114], CLL tumors and normal samples from Broad-2015 [115], CLL, Monoclonal B-cell lymphocytosis (MBL), and 24 SLL from ICGC-11 [92], and CLL from IUOPA-2015 [93]. Whole genome sequencing from 5 diffuse large B-cell lymphoma (DLBCL) studies, including normal samples: DLBCL from Duke-17 [97], DLBCL from BCGSC-13 [95], DLBCL from Broad-12 [96], DLBCL from DFCI-18 [94], and DLBCL from TCGA [98]. Whole genome sequencing from cutaneous T-cell lymphomas from 25 Sezary syndrome and cutaneous T-cell lymphomas (CTCL) from Columbia-15 [99], mantle cell lymphoma (MCL) from IDIBIPS-13 [100], and mature B-cell malignancies from MD Anderson [101]